Comments
Loading...

AnaptysBio Analyst Ratings

ANABNASDAQ
Logo brought to you by Benzinga Data
Consensus Rating1
Outperform
Highest Price Target1
$90.00
Lowest Price Target1
$20.00
Consensus Price Target1
$46.46

AnaptysBio Analyst Ratings and Price Targets | NASDAQ:ANAB | Benzinga

AnaptysBio Inc has a consensus price target of $46.46 based on the ratings of 16 analysts. The high is $90 issued by Guggenheim on May 28, 2025. The low is $20 issued by Truist Securities on December 18, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Guggenheim, and Guggenheim on June 4, 2025, May 28, 2025, and May 6, 2025, respectively. With an average price target of $60.67 between HC Wainwright & Co., Guggenheim, and Guggenheim, there's an implied 166.37% upside for AnaptysBio Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
3
1
Dec 24
3
2
Feb
1
1
Mar
3
May
1
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Guggenheim
Wedbush
JP Morgan
Wells Fargo

1calculated from analyst ratings

Analyst Ratings for AnaptysBio

Buy NowGet Alert
06/04/2025Buy Now66.85%HC Wainwright & Co.
Emily Bodnar38%
$22 → $38UpgradeNeutral → BuyGet Alert
05/28/2025Buy Now295.17%Guggenheim
Yatin Suneja54%
$54 → $90MaintainsBuyGet Alert
05/06/2025Buy Now137.1%Guggenheim
Yatin Suneja54%
$52 → $54MaintainsBuyGet Alert
05/01/2025Buy Now75.63%Wedbush
Martin Fan 51%
$40 → $40ReiteratesOutperform → OutperformGet Alert
03/05/2025Buy Now84.41%JP Morgan
Anupam Rama59%
$36 → $42MaintainsOverweightGet Alert
03/04/2025Buy Now-3.4%HC Wainwright & Co.
Emily Bodnar38%
$22 → $22ReiteratesNeutral → NeutralGet Alert
02/13/2025Buy Now123.93%Wells Fargo
Derek Archila60%
$40 → $51MaintainsOverweightGet Alert
02/12/2025Buy Now-3.4%HC Wainwright & Co.
Emily Bodnar38%
$19 → $22MaintainsNeutralGet Alert
02/07/2025Buy Now75.63%Wedbush
David Nierengarten62%
$40 → $40MaintainsOutperformGet Alert
02/04/2025Buy NowWolfe Research
Andy Chen43%
Initiates → OutperformGet Alert
02/04/2025Buy Now-16.58%HC Wainwright & Co.
Emily Bodnar38%
$19 → $19ReiteratesNeutral → NeutralGet Alert
12/19/2024Buy Now58.07%JP Morgan
Anupam Rama59%
$66 → $36MaintainsOverweightGet Alert
12/18/2024Buy Now-12.19%Truist Securities
John Lee1%
$30 → $20MaintainsHoldGet Alert
12/12/2024Buy Now75.63%Wells Fargo
Derek Archila60%
$56 → $40MaintainsOverweightGet Alert
12/12/2024Buy Now58.07%Guggenheim
Yatin Suneja54%
$90 → $36MaintainsBuyGet Alert
12/11/2024Buy NowHC Wainwright & Co.
Emily Bodnar38%
DowngradeBuy → NeutralGet Alert
12/02/2024Buy NowBTIG
Julian Harrison39%
DowngradeBuy → NeutralGet Alert
11/12/2024Buy Now189.79%JP Morgan
Anupam Rama59%
$75 → $66MaintainsOverweightGet Alert
11/06/2024Buy Now128.32%HC Wainwright & Co.
Emily Bodnar38%
$55 → $52MaintainsBuyGet Alert
10/31/2024Buy Now141.49%HC Wainwright & Co.
Emily Bodnar38%
$55 → $55ReiteratesBuy → BuyGet Alert
10/30/2024Buy Now44.89%UBS
Eliana Merle46%
$23 → $33MaintainsNeutralGet Alert
10/21/2024Buy Now295.17%Guggenheim
Yatin Suneja54%
$75 → $90MaintainsBuyGet Alert
09/26/2024Buy Now84.41%Wedbush
David Nierengarten62%
$42 → $42ReiteratesOutperform → OutperformGet Alert
08/15/2024Buy Now31.72%Truist Securities
John Lee1%
$20 → $30MaintainsHoldGet Alert
08/14/2024Buy Now141.49%HC Wainwright & Co.
Emily Bodnar38%
$55 → $55ReiteratesBuy → BuyGet Alert
08/07/2024Buy Now229.31%JP Morgan
Anupam Rama59%
$69 → $75MaintainsOverweightGet Alert
08/06/2024Buy Now141.49%HC Wainwright & Co.
Emily Bodnar38%
$55 → $55ReiteratesBuy → BuyGet Alert
07/22/2024Buy Now141.49%HC Wainwright & Co.
Emily Bodnar38%
→ $55Initiates → BuyGet Alert
07/19/2024Buy Now202.96%JP Morgan
Anupam Rama59%
$29 → $69UpgradeNeutral → OverweightGet Alert
05/10/2024Buy Now49.29%Wedbush
David Nierengarten62%
→ $34ReiteratesOutperform → OutperformGet Alert
04/16/2024Buy Now106.36%Leerink Partners
David Risinger71%
→ $47Initiates → OutperformGet Alert
04/11/2024Buy Now145.88%Wells Fargo
Derek Archila60%
→ $56Initiates → OverweightGet Alert
04/01/2024Buy Now22.94%JP Morgan
Anupam Rama59%
$30 → $28MaintainsNeutralGet Alert
03/12/2024Buy NowWedbush
David Nierengarten62%
UpgradeNeutral → OutperformGet Alert
02/26/2024Buy Now141.49%BTIG
Julian Harrison39%
→ $55Initiates → BuyGet Alert
02/21/2024Buy Now119.54%Stifel
Alex Schwartz42%
→ $50Initiates → BuyGet Alert
02/16/2024Buy Now251.26%Piper Sandler
Yasmeen Rahimi56%
→ $80Initiates → OverweightGet Alert
11/29/2023Buy Now-12.19%Wedbush
David Nierengarten62%
→ $20ReiteratesNeutral → NeutralGet Alert
11/03/2023Buy Now-12.19%Wedbush
David Nierengarten62%
$18 → $20MaintainsNeutralGet Alert
11/02/2023Buy Now-7.79%UBS
Eliana Merle46%
$28 → $21MaintainsNeutralGet Alert
08/08/2023Buy Now14.16%Wedbush
David Nierengarten62%
$29 → $26MaintainsNeutralGet Alert
05/22/2023Buy Now31.72%JP Morgan
Anupam Rama59%
$31 → $30UpgradeUnderweight → NeutralGet Alert
05/12/2023Buy Now27.33%Wedbush
David Nierengarten62%
→ $29ReiteratesNeutral → NeutralGet Alert
05/12/2023Buy Now97.58%Guggenheim
Yatin Suneja54%
$44 → $45MaintainsBuyGet Alert
04/12/2023Buy Now36.11%JP Morgan
Anupam Rama59%
$32 → $31MaintainsUnderweightGet Alert
01/06/2023Buy NowRaymond James
Timur Ivannikov41%
DowngradeOutperform → Market PerformGet Alert
11/18/2022Buy Now40.5%JP Morgan
Anupam Rama59%
$24 → $32MaintainsUnderweightGet Alert
11/09/2022Buy Now66.85%Raymond James
Steven Seedhouse57%
$30 → $38MaintainsOutperformGet Alert
11/01/2022Buy NowGuggenheim
Yatin Suneja54%
UpgradeNeutral → BuyGet Alert
09/19/2022Buy Now53.68%HC Wainwright & Co.
Gobind Singh19%
→ $35Assumes → BuyGet Alert
09/13/2022Buy Now22.94%Truist Securities
John Lee1%
$50 → $28DowngradeBuy → HoldGet Alert
09/01/2022Buy Now53.68%Raymond James
Steven Seedhouse57%
→ $35Initiates → OutperformGet Alert

FAQ

Q

What is the target price for AnaptysBio (ANAB) stock?

A

The latest price target for AnaptysBio (NASDAQ:ANAB) was reported by HC Wainwright & Co. on June 4, 2025. The analyst firm set a price target for $38.00 expecting ANAB to rise to within 12 months (a possible 66.85% upside). 29 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for AnaptysBio (ANAB)?

A

The latest analyst rating for AnaptysBio (NASDAQ:ANAB) was provided by HC Wainwright & Co., and AnaptysBio upgraded their buy rating.

Q

When was the last upgrade for AnaptysBio (ANAB)?

A

The last upgrade for AnaptysBio Inc happened on June 4, 2025 when HC Wainwright & Co. raised their price target to $38. HC Wainwright & Co. previously had a neutral for AnaptysBio Inc.

Q

When was the last downgrade for AnaptysBio (ANAB)?

A

The last downgrade for AnaptysBio Inc happened on December 11, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for AnaptysBio Inc.

Q

When is the next analyst rating going to be posted or updated for AnaptysBio (ANAB)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AnaptysBio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AnaptysBio was filed on June 4, 2025 so you should expect the next rating to be made available sometime around June 4, 2026.

Q

Is the Analyst Rating AnaptysBio (ANAB) correct?

A

While ratings are subjective and will change, the latest AnaptysBio (ANAB) rating was a upgraded with a price target of $22.00 to $38.00. The current price AnaptysBio (ANAB) is trading at is $22.78, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch